Cart
sales@molnova.com
Ascorbyl Propyl Hyaluronate
CAS No. 1800464-57-6
Ascorbyl Propyl Hyaluronate ( —— )
Catalog No. M23812 CAS No. 1800464-57-6
Ascorbyl propyl hyaluronate is a perfect combination of hyaluronic acid and vitamin C, to overcome the instability of vitamin C, is to improve wrinkles, moisturize, calm the skin, whitening quality raw materials.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 115 | In Stock |
|
| 50MG | 173 | In Stock |
|
| 100MG | 258 | In Stock |
|
| 200MG | 388 | In Stock |
|
| 500MG | 642 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAscorbyl Propyl Hyaluronate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAscorbyl propyl hyaluronate is a perfect combination of hyaluronic acid and vitamin C, to overcome the instability of vitamin C, is to improve wrinkles, moisturize, calm the skin, whitening quality raw materials.
-
DescriptionAscorbyl propyl hyaluronate is a perfect combination of hyaluronic acid and vitamin C, to overcome the instability of vitamin C, is to improve wrinkles, moisturize, calm the skin, whitening quality raw materials.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1800464-57-6
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Pomalidomide-C3-NH2 ...
Pomalidomide-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.
-
4,4'-Methylenediphen...
4,4'-Methylenediphenol is a high purity product from Gastrodia rhizome with antioxidant activities.
-
Monobutyl Phthalate
Used in organic synthesis, medicine industry.
